• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Look to the Whole-Body Effects of Drugs for Metastatic CNS Cancer, FDA Says

Look to the Whole-Body Effects of Drugs for Metastatic CNS Cancer, FDA Says

August 31, 2020

Trials of drugs to treat cancer in the central nervous system (CNS) that has metastasized from solid tumors outside the CNS should examine whether the treatment controls the cancer at all disease sites, according to an FDA draft guidance released last week.

Because metastatic cancer is a systemic disease, the guidance says, it is not enough to assess a drug by its ability to shrink tumors in the CNS alone. The guidance offers recommendations for the design of trials of systemic anticancer drugs that include patients with CNS metastases as well as trials conducted exclusively in patients with CNS metastases.

Efficacy claims based on endpoints measuring CNS activity alone “may not be appropriate,” and the same goes for labeling indications, the agency says, adding that the effectiveness of investigational cancer drugs depends on “whether the cancer is controlled at all disease sites.”

The FDA recommends that clinical trial designs for drugs to treat such cancers include case report forms that ask for information on all prior CNS-directed treatments patients may have received; that the protocol specify a gap of at least 12 weeks, generally, between patients’ completion of CNS radiation therapy and study entry; and that the protocol specify appropriate stratification factors for randomization to minimize bias based on prior treatments the patients may have undergone.

Study endpoints could include time-to-event, overall survival, tumor assessment, capture duration of response and time from prior radiation therapy.

Comments on the draft guidance are due Oct. 26.

Read the draft guidance here: https://bit.ly/2QxgYGz.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing